DP
Therapeutic Areas
Vanda Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| HETLIOZ® (tasimelteon) | Non-24-Hour Sleep-Wake Disorder (Non-24) | Approved |
| Fanapt® (iloperidone) | Schizophrenia | Approved |
| Fanapt® (iloperidone) one month injectable | Schizophrenia | In Development |
| NEREUS™ (tradipitant) | Atopic Dermatitis | Clinical Studies |
| BYSANTI™ (milsaperidone) | Bipolar I Disorder and Schizophrenia | Approved |
| Imsidolimab | Generalized Pustular Psoriasis | BLA Filed |
| PONVORY® (ponesimod) | Multiple Sclerosis (assumed) | Approved |
| Trichostatin A (TSA) | Hematologic Malignancies | Oncology Program |
Leadership Team at Vanda Pharmaceuticals
MH
Mihael H. Polymeropoulos, MD
President, Chief Executive Officer and Chairman of the Board
KM
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
JW
Joakim Wijkstrom
Senior Vice President, Chief Marketing Officer
GB
Gunther Birznieks
Senior Vice President, Business Development
TW
Tim Williams
Senior Vice President, General Counsel and Secretary
SH
Scott Howell
Chief People Officer
RW
Richard W. Dugan
Lead Independent Director, Board of Directors
SR
Stephen Ray Mitchell, MD, M.B.A.
Director, Board of Directors
PC
Phaedra Chrousos
Director, Board of Directors
AS
Anne Sempowski Ward
Director, Board of Directors